Substance Use Disorders in Older Adults: Recognition and Care

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

What Substance Use Disorders Mean in Later Life

Substance use disorders in older adults are clinically significant patterns of alcohol, medication, or other drug use that impair health, functioning, safety, or daily life. Recognition requires attention to changes in physiology, chronic illness, medication exposure, cognition, mobility, social circumstances, and the person's goals. Care combines careful diagnosis, treatment of the substance-specific disorder, appropriate management of coexisting conditions, prevention of overdose and dangerous withdrawal, and practical support for everyday functioning. Age alone neither establishes a disorder nor determines a person's capacity to recover. The central clinical question is whether substance-related problems are present, what mechanisms and risks are producing them, and which combination of services will help this individual. The U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) provides a dedicated clinical framework in Treating Substance Use Disorder in Older Adults, Treatment Improvement Protocol 26.

A person may use an alcohol-containing beverage or an appropriately prescribed medication without having a substance use disorder. Risky use refers to an exposure pattern that creates elevated harm, particularly in the setting of medical conditions or interacting medications. Medication misuse can include taking a drug differently from its prescribed directions, whether intentionally or through confusion; the term alone does not establish addiction. Substance use disorder requires a clinical pattern of impairment or distress assessed against substance-specific diagnostic criteria. Addiction describes a recurring clinical process involving impaired control and continued use despite adverse consequences, but is not interchangeable with every instance of tolerance or physical dependence. These distinctions matter especially when older patients have long-standing prescriptions or changes in memory and executive function. SAMHSA TIP 26 explicitly separates screening, assessment, and treatment planning.

How Common Are Substance Use Disorders Among Older Adults?

Older adults are a diverse population; the phrase commonly refers to people aged 65 and older in U.S. epidemiologic reporting, while clinical programs may include adults beginning at 50 or 55. Survey estimates depend on the age boundary, substance, diagnostic questions, participation, and setting. In the 2024 U.S. National Survey on Drug Use and Health, 8.0% of adults aged 65 or older met criteria for a past-year substance use disorder; 4.8% met criteria for alcohol use disorder and 3.8% for a drug use disorder. These percentages measure population prevalence under the survey's DSM-5-based definitions, and alcohol and drug categories overlap, so they should not be added to produce the total. SAMHSA 2024 detailed tables, Table 5.3B.

The prevalence of diagnosed disorder is only one part of the public health picture. Lower quantities of alcohol or medications may still cause major harm in a person with frailty, falls, liver or kidney impairment, sleep apnea, or a complex medication regimen. Conversely, a survey or clinical screening result cannot establish that every person reporting a substance has a disorder. Household surveys may not fully represent nursing-home residents, hospitalized patients, or people experiencing unstable housing, and cross-sectional figures do not identify causes. Clinical risk therefore depends on the patient in front of the practitioner as well as on national epidemiology. SAMHSA TIP 26, Chapter 1 provides the service-context perspective.

Why Aging Changes the Effects of Alcohol and Drugs

Distribution, metabolism, and clearance

With aging, changes in body water, body composition, liver function, renal clearance, and physiological reserve can modify drug exposure and effects. Two people consuming similar amounts can experience different levels of impairment. Older adults may reach a higher blood alcohol concentration after the same intake because of reduced total body water, while some medications remain active longer or accumulate when clearance is impaired. Individual variation is substantial; clinical decisions require current kidney and liver assessment rather than assumptions from chronological age. NIAAA, Aging and Alcohol and the CDC 2022 opioid prescribing guideline describe these concerns.

Neurocognitive vulnerability and functional reserve

Sedating substances can affect attention, reaction time, judgment, walking balance, and memory. A modest additional decline may turn previously compensated weakness, neuropathy, impaired vision, or mild cognitive impairment into a fall, medication error, driving incident, or episode of delirium. Neurocognitive symptoms should be evaluated clinically: substance effects, withdrawal, depression, sleep disturbance, dementia, and acute illness can overlap. The 2023 American Geriatrics Society Beers Criteria identify medication classes that increase delirium and fall risks in many older adults.

Polypharmacy and combinations

Polypharmacy means the use of multiple medicines, often for legitimate chronic conditions. Harm may arise from alcohol–medication, medication–medication, or drug–medication interactions even when each exposure is individually familiar. Opioids combined with benzodiazepines, alcohol, or other central nervous system depressants can suppress breathing. Gabapentinoids combined with opioids can compound sedation, and several central nervous system-active agents together increase fall risk. The safety assessment should include prescribed medicines, over-the-counter sleep aids and antihistamines, supplements, cannabis products, and alcohol, along with actual timing and use. These interaction risks are detailed in NIAAA's alcohol–medication review and the AGS Beers Criteria.

Late-Life Pathways: Long-Standing Use and New-Onset Problems

Some older adults have experienced recurrent substance-related problems for decades. Others increase drinking or medication use after retirement, bereavement, chronic pain, insomnia, reduced mobility, caregiving strain, loneliness, or changes in access to health care. These circumstances describe possible risk pathways; they are neither sufficient causes nor diagnostic criteria. Chronic stress can influence the reinforcing effects of substances, and persistent social isolation can reduce opportunities for early recognition. Detailed psychological mechanisms have their own canonical owners in How Addiction Affects the Brain: Reward, Learning, and Control and Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity.

A further pathway involves repeated medication exposure. A patient may become physically dependent on a prescribed benzodiazepine or opioid after sustained use without developing a substance use disorder; another patient may show impaired control, escalating unsanctioned use, compulsive acquisition, and repeated harms. Clinicians should review why a medication was prescribed, its current benefit, refill patterns, use against directions, other sedatives, and changes over time. The essential diagnostic judgment rests on behavior, context, function, and established criteria rather than on prescription status alone. ASAM's 2025 benzodiazepine tapering guideline distinguishes physical dependence and clinical treatment decisions.

Which Substances Require Particular Attention?

Alcohol

Alcohol is a central clinical concern because it is widely available and can interact with conditions and medications common in later life. Increased sensitivity can magnify cognitive symptoms, poor sleep, gait instability, dehydration, and falls. Heavy or sustained use can worsen liver disease, cardiovascular and gastrointestinal problems, depression, and nutritional deficiencies. Alcohol-related impairment sometimes presents as a medical complaint rather than a direct request for addiction care. NIAAA identifies memory loss, depressed mood, poor appetite, unexplained bruising, and falls as clues that merit a respectful conversation rather than an immediate assumption of diagnosis. NIAAA, Aging and Alcohol.

Alcohol use disorder is diagnosed from a problematic pattern causing clinically significant impairment or distress, evaluated through established substance-specific criteria and a full history. A low level of use may remain unsafe for a particular individual because of medical conditions or medication interactions without fulfilling disorder criteria. A brief conversation about consumption should therefore include health and functional risk, not only quantity. Proven therapies include appropriately selected medication treatment for alcohol use disorder and structured psychosocial interventions. Severe physiological dependence raises the possibility of dangerous withdrawal and requires a clinically supervised plan. SAMHSA TIP 26 and NIAAA's alcohol–medication resource.

Opioids and chronic pain

Opioid exposure in older adults can originate in chronic pain care, acute illness, surgery, or nonmedical use. Pain requires appropriate treatment even when opioid use disorder is present. A patient with opioid use disorder may show recurrent use despite harms, loss of control, and inability to fulfill valued activities; tolerance or withdrawal during medically supervised opioid therapy do not, by themselves, establish opioid use disorder. Renal and hepatic impairment, respiratory illness, sleep apnea, concurrent sedatives, and cognitive changes affect safety. CDC's Clinical Practice Guideline for Prescribing Opioids for Pain explicitly recommends added monitoring for adults aged 65 and older and attention to falls and cognitive impairment.

The available evidence supports medications for opioid use disorder, including buprenorphine and methadone, alongside continuing clinical and social support. Naltrexone may be appropriate for selected patients after assessment of opioid-free status and clinical suitability. Choice depends on patient preferences, access, coexisting conditions, medication interactions, and monitoring needs. A 2026 review focused on opioid use disorder in older adults concludes that medications remain central to care while older adults are underrepresented in many treatment studies. Opioid withdrawal management alone has inadequate protection against recurrence and overdose; Opioid Withdrawal: Symptoms, Timeline, and Treatment addresses that separate clinical question.

Benzodiazepines and other sedative-hypnotics

Benzodiazepines may be prescribed for specific clinical indications, but prolonged exposure in older age warrants periodic review of cognition, falls, driving, sedation, and interactions. Physical dependence is an expected possibility after sustained exposure and is distinct from compulsive use. A clinically important benzodiazepine use disorder requires diagnostic evaluation of impaired control and harms. Abrupt discontinuation in a physically dependent person can cause severe withdrawal, including seizures and delirium. A clinician should develop an individualized supervised plan when reduction is appropriate. ASAM's multidisciplinary 2025 guideline explicitly warns against abrupt discontinuation after sustained use; the AGS Beers Criteria describe heightened geriatric adverse effects.

Nonbenzodiazepine sleep medicines and sedating over-the-counter products can also impair cognition or balance. Their risks depend on compound, use pattern, comorbidities, and interactions. Patients benefit from a complete reconciliation of prescription, nonprescription, and borrowed medicines rather than a stigmatizing inquiry restricted to illegal drugs. Sleep complaints call for evaluation of sleep disorders, mood symptoms, medications, alcohol, pain, and behavioral sleep treatments where appropriate. SAMHSA TIP 26, Chapter 5.

Cannabis and other psychoactive substances

Cannabis use among older adults warrants assessment of product composition, potency, route, frequency, reason for use, and accompanying medicines. Acute impairment, dizziness, anxiety, cognition changes, and possible interactions can compromise driving and fall safety. Evidence for some proposed medical benefits remains condition-specific and heterogeneous; self-reported relief is not equivalent to proof of treatment efficacy. Cannabis use disorder requires clinical criteria involving impaired control, consequences, and persistence. A cannabis screening score is a prompt for assessment, not a diagnosis. SAMHSA TIP 26, Chapter 3 discusses the CUDIT-R and warns that threshold validation is limited in older adults.

Stimulants such as cocaine and methamphetamine can produce acute cardiovascular and neuropsychiatric complications. In an older person with vascular disease or arrhythmia, chest pain, stroke-like symptoms, severe agitation, high body temperature, or psychosis require urgent medical assessment. Tobacco and nicotine dependence also remain clinically important; smoking cessation improves health across older ages, and there are evidence-based pharmacological and behavioral options. The substance-specific cessation approach is developed in How to Quit Smoking: Effective Medications and Behavioral Support. SAMHSA TIP 26, Chapter 5 provides an older-adult care overview.

Warning Signs: How Substance Problems Can Present in Older Adults

Older adults may seek care for falls, dizziness, declining memory, changing mood, poor nutrition, reduced self-care, daytime sleepiness, missed medications, recurrent emergency visits, or worsening chronic disease. These are nonspecific findings with many medical and psychological causes. They justify a clinical question about substances and medicines and a differential assessment, not a presumptive label of addiction. A new social withdrawal pattern, increasingly isolated drinking, inaccurate pill counts, unexplained sedation, recurrent early refill requests, or using medication for reasons other than its prescription can provide additional context. NIAAA, Aging and Alcohol and SAMHSA TIP 26, Chapter 3.

Collateral information from family or caregivers may be useful with the patient's permission, especially when memory or communication is impaired. The assessment should protect privacy and autonomy while evaluating decisional capacity when clinically necessary. A clinician should ask what has changed, when symptoms started, whether they correlate with doses or drinking occasions, and what happens during periods without exposure. Medication records and pharmacy review may reveal confusing duplications or multiple prescribers. Laboratory data, vital signs, cognition screening, gait assessment, and examination may illuminate consequences or differential diagnoses, but no single blood test or behavioral sign diagnoses a substance use disorder. SAMHSA TIP 26.

Screening, Clinical Assessment, and Diagnosis

Screening opens the conversation

Screening is an efficient first step to identify a possible risk that deserves conversation or assessment. It is not an adjudication of character, intentionality, or diagnosis. The USPSTF recommends screening adults for unhealthy alcohol use in primary care and offering brief behavioral counseling to adults with risky or hazardous drinking. The AUDIT-C and single alcohol screening question are commonly used; accuracy and optimal cutoffs can vary with age and clinical context. The 2018 USPSTF recommendation remains a relevant recommendation while an update is in progress.

Older-adult-oriented approaches include the Short Michigan Alcoholism Screening Test—Geriatric Version (SMAST-G), Comorbidity Alcohol Risk Evaluation Tool (CARET), and other context-sensitive questions about alcohol use with medications or medical illnesses. SAMHSA discusses strengths and limits of available tools and cautions against assuming a negative brief screen rules out a clinically relevant concern. Evidence for some screening tools in older or cognitively impaired populations is limited; clinicians should interpret answers alongside functioning, collateral history, and medication reconciliation. SAMHSA TIP 26, Chapter 3.

Clinical assessment establishes context

A comprehensive assessment documents which substances are used; amounts, frequency, route, and duration; prescribed indications and actual medication-taking behavior; timing of intoxication or withdrawal symptoms; prior treatment; overdose or seizures; and medical, psychiatric, and social conditions. It also examines sleep, pain, falls, cognition, nutrition, hearing, vision, mobility, living conditions, suicide risk, and the patient's understanding of the problem. Laboratory testing and toxicology may help with selected clinical questions, but results have detection windows, limitations, and potential confounders. An unexpected result requires discussion and interpretation, especially when a medication has been prescribed. SAMHSA TIP 26.

Where possible, clinicians should distinguish substance effects from delirium, neurodegenerative disease, depression, metabolic conditions, medication toxicity, vestibular disorders, and other causes of deterioration. The key question is temporal: what occurred before the symptom, what substances or drugs were taken, and what changed during treatment or periods of reduced exposure? Some symptoms have multiple simultaneous causes. The clinical team's role is to integrate the evidence into a working formulation and revisit it as functioning changes. AGS Beers Criteria and CDC opioid guidance.

Diagnostic standards and their limits

DSM-5-TR diagnoses substance use disorders using a substance-specific collection of criteria that evaluate impaired control, social impairment, risky use, and pharmacological features within a defined period. For some medically prescribed substances, tolerance and withdrawal during appropriate medical supervision do not count as disorder criteria. Severity is based on the number of criteria met, while treatment intensity depends additionally on clinical instability, withdrawal risk, medical comorbidity, environment, and functional needs. Older-adult assessment should therefore avoid equating physical dependence with addiction and should avoid dismissing serious harms merely because reported consumption is low. SAMHSA TIP 26 and Addiction Severity and Level of Care: How Treatment Needs Are Assessed.

Some DSM criteria may manifest differently after retirement or disability: obligations and social roles change, and older patients may have fewer contexts in which hazardous use becomes visible. The absence of workplace problems cannot substitute for an evaluation of home safety, relationships, mobility, independent living, or medical consequences. Cognitive changes may affect reliable reporting, while shame and expectations about aging may suppress disclosure. The diagnostic framework remains valid, but its application must be sensitive to late-life context. SAMHSA TIP 26, Chapter 3.

Clinical Differential Diagnosis: Substance Effect, Medical Illness, or Both?

Delirium and dementia

Delirium is an acute disturbance in attention and awareness, often fluctuating and associated with medical illness, medication toxicity, intoxication, or withdrawal. Dementia involves a longer-term pattern of cognitive decline, although the conditions can coexist. Sudden confusion in an older adult is a medical urgency and requires evaluation for infection, metabolic disruption, stroke, medication problems, and substance-related causes. Persistent memory difficulty after intoxication resolves may call for further neurocognitive evaluation. Alcohol-related deficits, sedative effects, and nutritional conditions may complicate the picture. The AGS Beers Criteria highlight several medicines capable of worsening delirium.

Depression, anxiety, grief, and sleep problems

Mood and anxiety symptoms may precede substance use, arise from it, worsen during withdrawal, or coexist independently. Insomnia can increase alcohol or sedative use; alcohol can then fragment sleep and reinforce a cycle of impairment. Grief and loneliness deserve direct assessment as real clinical and social concerns rather than being reduced to substance misuse. When severe depression or suicidality is present, urgent safety assessment and coordinated mental health care are needed alongside substance treatment. This article addresses geriatric recognition and integrated care; the distinct comorbidity mechanism is explored in Anxiety and Substance Use. NIAAA.

Pain, neurological illness, and medication adverse effects

Worsening pain may drive an increase in sedative or opioid use, while uncontrolled pain, neuropathy, Parkinsonian syndromes, orthostatic hypotension, and medication adverse effects can create symptoms that resemble intoxication. Careful examination, medication review, and an understanding of the patient's pain goals are essential. When opioid use disorder and chronic pain coexist, both require treatment; the presence of addiction should not lead to untreated pain. The CDC 2022 guideline calls for individualized multimodal pain treatment and careful monitoring in older adults.

Assessing Safety and Choosing a Level of Care

Clinical urgency is determined by the full clinical presentation. Severe intoxication, inability to remain awake, slow or absent breathing, a suspected opioid overdose, seizures, severe withdrawal, sudden confusion, chest pain, stroke symptoms, severe dehydration, acute psychosis, or immediate risk of self-harm warrants emergency assessment. When overdose is suspected, contact emergency services. If opioid exposure is possible, administer naloxone when available according to its device instructions, and follow emergency dispatcher guidance for breathing and resuscitation. Naloxone can reverse opioid-related respiratory depression temporarily, and emergency assessment is needed even if the person becomes responsive. CDC guidance on naloxone and opioid risk.

Alcohol and benzodiazepine withdrawal can be life-threatening and may involve seizures or delirium. Patients with physiological dependence, prior severe withdrawal, significant medical illness, unstable housing, or poor access to monitoring need professional assessment before any change in use. Self-directed abrupt discontinuation, rapid taper schedules, or substitution with other sedatives can be dangerous. The ASAM benzodiazepine tapering guideline and SAMHSA TIP 26 support individualized, monitored treatment decisions.

For a medically stable patient, outpatient care may be appropriate if clinical monitoring, medication management, and supports are sufficient. Intensive outpatient, residential, hospital, or medically managed withdrawal services may be warranted when safety, complexity, or functional capacity requires them. The purpose of assessment is to identify needs and match intensity, not to rank patients morally by severity. A plan should include falls prevention, cognitive accommodations, reliable transport, physical accessibility, and coordination between primary care, addiction services, pharmacy, and behavioral health. Addiction Severity and Level of Care.

Evidence-Based Treatment of Substance Use Disorders in Older Adults

Patient-centered, integrated care

The first clinical step is collaborative treatment planning: identify the patient's goals, clinically significant risks, priorities for daily function, resources, and barriers. A person may prioritize remaining independent, sleeping better, reducing falls, improving family contact, or managing pain safely. An effective care plan translates these concerns into measurable clinical and functional outcomes. Integrated care is especially important where several clinicians prescribe medication or where sensory, cognitive, and physical limitations make fragmented services difficult to use. SAMHSA TIP 26.

Age-responsive services may use a slower pace, clear written instructions, teach-back to confirm understanding, hearing or visual accommodations, transportation assistance, and coordination with a caregiver if the patient agrees. These are clinical access accommodations, not a different definition of addiction. A patient's preferences and capacity should shape how information is shared and how appointments are arranged. Referral alone may fail when cost, travel, disability access, caregiving responsibilities, or stigma remains unresolved. SAMHSA TIP 26, Chapter 5.

Brief interventions and motivational approaches

Brief behavioral counseling can reduce unhealthy alcohol use in adult primary care populations. A Cochrane review of brief alcohol interventions found a modest reduction in average consumption compared with minimal or no intervention, but relatively few trials enrolled older adults specifically. In a broader evidence synthesis informing the USPSTF, counseling reduced mean weekly alcohol consumption and some high-risk patterns, while trial quality and group representation varied. For an established severe substance use disorder, brief advice alone should not substitute for comprehensive treatment. USPSTF evidence summary.

Motivational interviewing uses collaborative discussion to clarify personal goals and ambivalence. Cognitive behavioral treatments can address cues, coping, sleep, problem-solving, and behavioral routines. Family-informed approaches can help where communication, medication management, or caregiver stress intersects with recovery. In older adults, benefits are plausible and supported by general adult evidence, but the precise comparative effectiveness of each format in frail, cognitively impaired, or medically complex older populations remains less certain. SAMHSA TIP 26, Chapter 7 outlines age-responsive psychosocial supports.

Medication for alcohol use disorder

For diagnosed alcohol use disorder, medications such as naltrexone and acamprosate have an evidence base in adult populations. Choice depends on treatment goals, opioid exposure, kidney and liver function, medical conditions, and medication interactions. Naltrexone must not be initiated in someone currently dependent on opioids or receiving opioid agonist treatment, because opioid blockade can precipitate withdrawal and interfere with necessary analgesia. Acamprosate requires attention to renal function. Disulfiram has important safety and adherence considerations and is not a universal first-line choice for medically complex older adults. Prescribing decisions belong to clinicians who can assess the full medication list and monitor treatment. SAMHSA TIP 26 and a Cochrane review of acamprosate.

The strongest pharmacotherapy evidence comes largely from adults of mixed ages. Patients with severe organ dysfunction, advanced frailty, or major cognitive impairment are often less represented in trials. Older age alone is not a reason to withhold potentially beneficial treatment; it is a reason to evaluate organ function, tolerability, adherence support, and interactions carefully. Treatment should address physical health, nutrition, sleep, and mental health as well as drinking outcomes. SAMHSA TIP 26, Chapter 4.

Medication for opioid use disorder

Buprenorphine and methadone reduce the harms associated with opioid use disorder when appropriately delivered and continued; they are ongoing treatment options rather than short-term detoxification devices. Extended-release naltrexone is suitable for some patients following necessary clinical evaluation and full opioid withdrawal, but initiating opioid antagonism in the presence of opioids can precipitate withdrawal. Selection depends on patient circumstances, treatment access, medical risk, and preference. In older adults, clinicians should evaluate respiratory conditions, sedation, falls, cardiac risk where relevant, drug interactions, and treatment logistics. The 2026 review of older-adult OUD emphasizes individualized medication treatment despite gaps in direct geriatric trials.

Care should remain available after emergency visits or withdrawal treatment, with naloxone access for patients at risk and education for willing caregivers. Concurrent benzodiazepines call for careful risk management, clinical coordination, and avoidance of abrupt unsafe changes; their presence should prompt a structured safety plan rather than abandonment of opioid use disorder treatment. Discontinuing opioid agonist treatment without support can create overdose risk when tolerance falls and use recurs. CDC opioid guideline; ASAM benzodiazepine tapering guideline.

Sedative-related disorders and other substance-specific care

Treatment of problematic benzodiazepine use requires distinguishing appropriate use with dependence from a diagnosable disorder, coordinating prescribers, identifying co-occurring substance use, and managing withdrawal safely. Where reduction is indicated, the approach is gradual, individualized, supervised, and revised according to response. Psychotherapy and effective treatment of the original anxiety or sleep condition help address why use became persistent. ASAM 2025 guidance.

For stimulant use disorders, behavioral interventions, including contingency management in appropriate clinical programs, have an evidence base; there is no universally established medication equivalent to opioid agonist treatment. For cannabis-related problems, motivational and cognitive behavioral approaches may be considered while recognizing variable evidence and the paucity of geriatric-specific trials. Tobacco treatment can include approved smoking-cessation medications and counseling when clinically suitable. The best choice varies by substance, co-occurring illness, and availability. SAMHSA TIP 26, Chapter 5.

Recovery, Remission, and Everyday Function

Recovery can be evaluated through substance use patterns, diagnostic remission, physical and mental health, social connection, autonomy, and the ability to perform meaningful activities. Remission is a diagnostic designation tied to criteria over time; recovery is broader and can include improved housing stability, mobility, medical adherence, relationships, and purpose. Recurrence of use requires assessment of immediate safety, changed treatment needs, and available support. It does not erase previous health gains. The separate diagnostic and prognostic intent is covered by Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis.

For an older adult, a meaningful improvement might be fewer falls, more reliable medication management, reduced emergency care, better sleep, repaired family communication, or regained participation in community life. Some patients seek abstinence; other situations require goals shaped by risk, health conditions, treatment, and clinical judgment. Opioid agonist medication can be part of sustained recovery. Progress should be reviewed over time because aging, bereavement, illness, changes in cognition, and caregiving responsibilities can alter both risks and available supports. SAMHSA TIP 26.

Harm Reduction and Prevention in Later Life

Harm reduction aims to lower preventable illness, injury, and death while maintaining pathways to treatment. For older people, practical strategies include access to naloxone where opioid overdose risk exists, coordinated medication review, minimizing risky combinations of sedatives, safer storage, clear dispensing systems, falls assessment, transportation and mobility supports, and medical follow-up. Education about overdose warning signs should reach patients and willing family members or caregivers. Because substance-related harm may occur without a substance use disorder, harm reduction belongs in routine geriatric health care as well as specialist addiction services. CDC opioid guidance and NIAAA alcohol–medication guidance.

Prevention also includes asking about alcohol before prescribing interacting medications, reviewing use during transitions between hospital and home, identifying unmet pain or sleep needs, and reducing practical barriers to counseling and medication treatment. Public health messaging should reflect that treatment works across the lifespan and avoid equating aging with inevitable decline. The efficacy of a specific prevention program should be evaluated separately from the general plausibility of its components. SAMHSA TIP 26, Chapter 2.

Family, Caregiver, and Care-System Considerations

Family members may first observe missed meals, intoxication, recurrent falls, medication disorganization, or changes in behavior. They can describe observable patterns and encourage assessment while respecting privacy and the adult's decision-making rights. A caregiver should not remove or rapidly change medications on their own, especially when alcohol or benzodiazepine dependence is possible. Collaborative plans can clarify how to respond to emergencies, how to communicate with clinicians, and how to assist with transport or medication organization if welcomed. SAMHSA TIP 26.

Services also need to consider disparities in access. Rural distance, cost, insurance limitations, stigma, limited transportation, hearing or vision loss, language barriers, and the assumption that treatment is only for younger people can impede care. People living in institutions, experiencing homelessness, belonging to marginalized groups, or caring for a spouse may have distinct constraints. An equitable approach offers flexible service delivery and accessible communication without stereotyping the person's motivation or prognosis. Available studies often recruit healthier and more mobile volunteers, so outcomes from those samples may generalize incompletely to the most medically complex older adults. SAMHSA TIP 26, Chapters 1 and 2.

What Does the Evidence Establish, and Where Are the Gaps?

Established evidence supports screening for unhealthy alcohol use in adults, brief behavioral interventions for many risky drinkers, and substance-specific treatment for diagnosed disorders. Established pharmacologic treatments for alcohol and opioid use disorders are grounded chiefly in general-adult research, with geriatric prescribing adapted to medical complexity. The AGS and ASAM guidelines provide strong clinical warnings about high-risk sedative combinations and abrupt benzodiazepine cessation. These are evidence-based clinical principles, although the precision of treatment effect sizes for patients aged 75 or 85 with multimorbidity is often unknown. USPSTF, AGS, and ASAM.

Evidence is more limited for the diagnostic accuracy of some brief screeners among people with dementia or substantial frailty, for head-to-head comparisons of geriatric-specific psychosocial programs, and for long-term outcomes across the oldest age bands. The 2018 USPSTF evidence review included relatively few older-adult intervention studies; the 2026 older-adult opioid review describes corresponding gaps in medication and assessment research. Much observational epidemiology cannot resolve whether loneliness, illness, medication exposure, or substance use is a cause, consequence, or correlated part of a more complex process. These uncertainties support better longitudinal and pragmatic research, not clinical inaction. USPSTF evidence summary; Hannan and colleagues, 2026.

Frequently Asked Questions

Can someone develop a substance use disorder for the first time after 65?

Yes. Clinically significant problems can first emerge in later life when patterns of alcohol or medication use change, or when illness and living circumstances alter vulnerabilities. A new problem deserves the same diagnostic care as a long-standing one, including attention to potentially reversible contributors such as pain, sleep disturbance, bereavement, depression, and medication interactions. SAMHSA TIP 26.

Do falls or memory problems mean an older person has addiction?

No single symptom determines that diagnosis. Falls and memory changes can result from neurological disease, illness, medications, intoxication, withdrawal, or combinations of causes. They warrant prompt clinical evaluation, a complete medication and substance history, and functional assessment. Acute confusion, head injury, or impaired consciousness requires urgent medical assessment. NIAAA, Aging and Alcohol.

Is prescription opioid dependence the same as opioid use disorder?

Physical dependence is a physiological adaptation that may occur with sustained appropriate treatment. Opioid use disorder is diagnosed from clinically significant patterns of impaired control and consequences according to criteria. Clinicians must account for medically supervised prescribing, pain treatment, and patient functioning. CDC 2022 opioid guideline.

Can an older adult safely stop drinking or stop benzodiazepines at home?

An abrupt stop can be dangerous when significant physiological dependence exists. Alcohol or benzodiazepine withdrawal may cause seizures, delirium, and other emergencies. A clinician should assess withdrawal risk and determine the safest setting and plan; the person should not follow an unsupervised rapid-discontinuation schedule. ASAM benzodiazepine tapering guidance and SAMHSA TIP 26.

Is treatment effective for people in their 70s or 80s?

Effective substance use disorder treatment can be offered in older age. Appropriately selected medications, behavioral therapy, and continued recovery support are used while accounting for organ function, cognition, mobility, patient preference, and medical conditions. Direct randomized evidence for the oldest and frailest groups is thinner than the general-adult evidence; decisions should balance individualized benefits and risks. SAMHSA TIP 26 and Hannan and colleagues, 2026.

What should relatives do when they notice a possible problem?

Describe specific concerns without accusation, encourage a health care visit and comprehensive medication review, and help remove practical obstacles to care when the older adult agrees. For suspected overdose, severe withdrawal, a seizure, or sudden confusion, seek emergency medical services. Families can help provide context, but diagnosis and medication changes should be led by qualified professionals. SAMHSA TIP 26.

Conclusion

Substance use disorders in older adults are recognizable and treatable clinical conditions whose presentation is shaped by physiology, medication interactions, cognitive and functional change, co-occurring illness, and social circumstances. Accurate care begins with a substance-specific history and differentiated screening and diagnosis, proceeds through assessment of safety and medical complexity, and combines proven treatments with individualized recovery supports. Across later life, meaningful outcomes include safer medication use, fewer injuries, better health, sustained engagement with care, and restored participation in valued activities.

Related Articles

Addiction Severity and Level of Care: How Treatment Needs Are Assessed — Clinical placement and multidimensional treatment planning.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — Distinguishing anxiety, withdrawal, and co-occurring conditions.

Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis — Diagnostic remission and long-term prognosis.

How to Quit Smoking: Effective Medications and Behavioral Support — Evidence-based nicotine cessation care.

Opioid Withdrawal: Symptoms, Timeline, and Treatment — Opioid withdrawal and its clinical management.

References

American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71, 2052–2081. https://doi.org/10.1111/jgs.18372.

American Society of Addiction Medicine and partner societies. (2025). Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Benzodiazepine Risks Outweigh Benefits. https://www.asam.org/quality-care/clinical-guidelines/benzodiazepine-tapering.

Centers for Disease Control and Prevention. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Morbidity and Mortality Weekly Report, 71(RR-3), 1–95. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm.

Hannan, J. K., McCracken, L., Romero-Ortiz, J. A., Warren, M. W., and Barnett, M. C. (2026). Considerations for Opioid Use Disorder in Older Adults. Current Addiction Reports, 13, Article 72. https://doi.org/10.1007/s40429-026-00776-6.

Kaner, E. F. S., and colleagues. (2018). Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database of Systematic Reviews, CD004148. https://www.cochrane.org/evidence/CD004148_effectiveness-brief-alcohol-interventions-primary-care-populations.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Aging and Alcohol. https://www.niaaa.nih.gov/alcohols-effects-health/aging-and-alcohol.

National Institute on Alcohol Abuse and Alcoholism. (2025). Alcohol-Medication Interactions: Potentially Dangerous Mixes. https://www.niaaa.nih.gov/health-professionals-communities/core-resource-on-alcohol/alcohol-medication-interactions-potentially-dangerous-mixes.

Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., and Soyka, M. (2010). Acamprosate for alcohol dependent patients. Cochrane Database of Systematic Reviews, CD004332. https://www.cochrane.org/evidence/CD004332_acamprosate-alcohol-dependent-patients.

Substance Abuse and Mental Health Services Administration. (2020). Treating Substance Use Disorder in Older Adults. Treatment Improvement Protocol (TIP) Series 26. https://www.ncbi.nlm.nih.gov/books/NBK571029/.

Substance Abuse and Mental Health Services Administration. (2024). Results from the 2024 National Survey on Drug Use and Health: Detailed Tables, Table 5.3B. https://www.samhsa.gov/data/sites/default/files/reports/rpt56484/NSDUHDetailedTabs2024/NSDUHDetailedTabs2024/2024-nsduh-detailed-tables-sect5pe.htm.

U.S. Preventive Services Task Force. (2018). Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions.

U.S. Preventive Services Task Force. (2018). Evidence Summary: Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions.